The hospital in September 2016 introduced the oral care bundle, which ensures patients undergoing chemotherapy maintain good oral hygiene to reduce infection risks.
The American Cancer Society recommended that individuals begin colorectal cancer screening at age 45, five years earlier than previous guidelines. The change reflects a rise in colon and rectal cancer cases and deaths among adults under 50.
Women who use the breast cancer drug Herceptin for six months did just as well as those who took it for a year, according to a new study that could ultimately benefit value-based providers and harm those still based on fee-for-service models.
Whether to get screened for prostate cancer is a question that men ages 55 to 69 should decide themselves in consultation with their doctors, according to finalized guidance issued Tuesday by an influential panel of healthcare experts.
Cancer patients can connect and be supported by others fighting the disease with a free patient navigation app.
A treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much of its success in less common cancers.
Henry Ford Health System received an anonymous $20 million gift that will fund the Henry Ford Pancreatic Cancer Center, the tentative name for a global consortium of researchers that will seek to develop better methods for earlier detection of the disease.
Coffee can cause cancer? Many coffee drinkers are skeptical about the California judge's recent ruling on labeling cancer warnings on coffee purchased in the state.
A network of Chicago-area providers are working together to address cancer patients' needs beyond just healthcare services.
The CMS will now cover diagnostic laboratory tests using gene sequencing technology for Medicare cancer patients. The agency said the tests can help patients and their oncologists make better treatment decisions.
Cancer specialists are urging physicians and patients to consider testing for gene mutations tied to prostate cancer, though questions linger about its cost-effectiveness.
The U.S. Preventive Services Task Force is discouraging ovarian cancer screening for asymptomatic women, saying it's ineffective and has a high incidence of false-positives and doesn't curb mortality rates.